ACCL vs JBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

ACCL

51.2
AI Score
VS
JBIO Wins

JBIO

52.1
AI Score

Investment Advisor Scores

ACCL

51score
Recommendation
HOLD

JBIO

52score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ACCL JBIO Winner
Net Income 1.02M -40.37M ACCL
Operating Income 1.08M -43.45M ACCL
ROE 46.7% -13.6% ACCL
ROA 26.1% -12.6% ACCL
Total Assets 3.91M 319.43M JBIO
Cash 2.45M 55.09M JBIO
Current Ratio 1.82 14.29 JBIO
Free Cash Flow 1.51M -24.28M ACCL

Relative Price Performance (Last 90 Days)

ACCL 1M: +33.1% · 3M: +48.7% JBIO 1M: -11.0% · 3M: -21.0%

Current Technical Phase

ACCL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 78

RSI (14): 78.2 · Price: $2.29

JBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 42

RSI (14): 42.1 · Price: $19.15

Fundamentals Snapshot

Metric ACCL JBIO
Market Cap
Forward P/E 0.0 -8.7
Trailing P/E 55.8
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.4%
Operating Margin 0.0% 0.0%
EPS 0.04 -2.72
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, JBIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.